Journal of Otorhinolaryngology and Facial Plastic Surgery

1. Barbiellini Amidei C, Salmaso L, Bellio S, Saia M. Epidemiology of traumatic spinal cord injury: a large population-based study. Spinal cord. 2022;60(9):812-9.

2. Lu Y, Shang Z, Zhang W, Pang M, Hu X, Dai Y, et al. Global incidence and characteristics of spinal cord injury since 2000–2021: a systematic review and meta-analysis. BMC medicine. 2024;22(1):285.

3. Wyndaele M, Wyndaele J-J. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey? Spinal cord. 2006;44(9):523-9.

4. Bhatt M, Das B. Advancements in spinal cord injury treatment: integrating drug delivery, biophysical stimulation, cell-based therapies, and tissue engineering approaches. ACS Applied Bio Materials. 2025;8(8):6526-40.

5. Anjum A, Yazid MDi, Fauzi Daud M, Idris J, Ng AMH, Selvi Naicker A, et al. Spinal cord injury: pathophysiology, multimolecular interactions, and underlying recovery mechanisms. International journal of molecular sciences. 2020;21(20):7533.

6. Hachem LD, Fehlings MG. Pathophysiology of spinal cord injury. Neurosurgery Clinics. 2021;32(3):305-13.

7. Alizadeh A, Dyck SM, Karimi-Abdolrezaee S. Traumatic spinal cord injury: an overview of pathophysiology, models and acute injury mechanisms. Frontiers in neurology. 2019;10:282.

8. Hou J, Klippel K, Bose P. Glutamate excitotoxicity: a key secondary injury mechanism of traumatic brain injury and spinal cord injury. Frontiers in Bioscience-Landmark. 2025;30(10):38904.

9. Yu M, Wang Z, Wang D, Aierxi M, Ma Z, Wang Y. Oxidative stress following spinal cord injury: from molecular mechanisms to therapeutic targets. Journal of Neuroscience Research. 2023;101(10):1538-54.

10. Gensel JC, Zhang B. Macrophage activation and its role in repair and pathology after spinal cord injury. Brain research. 2015;1619:1-11.

11. Hu Y, Gao J. The role of polarization dynamics in macrophages and microglia on the inflammatory microenvironment of spinal cord injury. Molecular and Cellular Neuroscience. 2025:104054.

12. Badhiwala JH, Ahuja CS, Fehlings MG. Time is spine: a review of translational advances in spinal cord injury: JNSPG 75th Anniversary Invited Review Article. Journal of Neurosurgery: Spine. 2018;30(1):1-18.

13. Karsy M, Hawryluk G. Modern medical management of spinal cord injury. Current Neurology and Neuroscience Reports. 2019;19(9):65.

14. Fehlings MG, Wilson JR, Cho N. Methylprednisolone for the treatment of acute spinal cord injury: counterpoint. Neurosurgery. 2014;61(CN_suppl_1):36-42.

15. Ahuja CS, Martin AR, Fehlings M. Recent advances in managing a spinal cord injury secondary to trauma. F1000Research. 2016;5:F1000 Faculty Rev-17.

16. Riza YM, Alzahrani FA. Rewiring the Spine—Cutting-Edge Stem Cell Therapies for Spinal Cord Repair. International Journal of Molecular Sciences. 2025;26(11):5048.

17. Wu Y, Wang Y, Zhou J, Tang Z, Huang L, Liu S. How advanced are exosomes as cell-free therapeutics for spinal cord injury? International Journal of Nanomedicine. 2025:11669-83.

18. Shkap M, Namestnikova D, Cherkashova E, Chudakova D, Biktimirov A, Yarygin K, et al. Clinical insights into mesenchymal stem cell applications for spinal cord injury. International Journal of Molecular Sciences. 2025;26(24):12139.

19. Rahman K. 'Epidemiology of people with disability in one selected area at Savar Upazilla': Bangladesh Health Professions Institute, Faculty of Medicine, the University …; 2023.

20. Merritt CH, Taylor MA, Yelton CJ, Ray SK. Economic impact of traumatic spinal cord injuries in the United States. Neuroimmunology and neuroinflammation. 2019;6:9.

21. Oyinbo C. Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade. Acta neurobiologiae experimentalis. 2011;71(2):281-99.

22. Jiang Z, Zhang C, Zhao Z, Ning B. Blood–spinal cord barrier disruption after spinal cord injury: a time-dependent mechanistic review. Frontiers in Cellular Neuroscience. 2026;20:1805529.

23. Liu X, Zhang Y, Wang Y, Qian T. Inflammatory response to spinal cord injury and its treatment. World neurosurgery. 2021;155:19-31.

24. Park E, Velumian AA, Fehlings MG. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. Journal of neurotrauma. 2004;21(6):754-74.

25. Tran AP, Warren PM, Silver J. New insights into glial scar formation after spinal cord injury. Cell and tissue research. 2022;387(3):319-36.

26. Ortega MA, Fraile-Martinez O, García-Montero C, Haro S, Álvarez-Mon MÁ, De Leon-Oliva D, et al. A comprehensive look at the psychoneuroimmunoendocrinology of spinal cord injury and its progression: mechanisms and clinical opportunities. Military Medical Research. 2023;10(1):26.

27. Vafaei-Nezhad S, Niknazar S, Norouzian M, Abdollahifar M-A, Aliaghaei A, Abbaszadeh HA. Therapeutics effects of [Pyr1] apelin-13 on rat contusion model of spinal cord injury: an experimental study. Journal of Chemical Neuroanatomy. 2021;113:101924.

28. Hurlbert RJ. Strategies of medical intervention in the management of acute spinal cord injury. Spine. 2006;31(11S):S16-S21.

29. Bowers CA, Kundu B, Hawryluk GW. Methylprednisolone for acute spinal cord injury: an increasingly philosophical debate. Neural regeneration research. 2016;11(6):882.

30. Fehlings MG, Wilson JR, Tetreault LA, Aarabi B, Anderson P, Arnold PM, et al. A clinical practice guideline for the management of patients with acute spinal cord injury: recommendations on the use of methylprednisolone sodium succinate. Global spine journal. 2017;7(3_suppl):203S-11S.

31. Nori S, Ahuja CS, Fehlings MG. Translational advances in the management of acute spinal cord injury: what is new? What is hot? Neurosurgery. 2017;64(CN_suppl_1):119-28.

32. Cheah B, Vucic S, Krishnan A, Kiernan M. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Current medicinal chemistry. 2010;17(18):1942-59.

33. Fehlings MG, Moghaddamjou A, Harrop JS, Stanford R, Ball J, Aarabi B, et al. Safety and efficacy of riluzole in acute spinal cord injury study (RISCIS): a multi-center, randomized, placebo-controlled, double-blinded trial. Journal of neurotrauma. 2023;40(17-18):1878-88.

34. Noble W, Garwood CJ, Hanger DP. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfolding. Prion. 2009;3(2):78-83.

35. Casha S, Zygun D, McGowan MD, Bains I, Yong VW, John Hurlbert R. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain. 2012;135(4):1224-36.

36. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. The neuroscientist. 2005;11(4):308-22.

37. Forgione N, Fehlings MG. Rho-ROCK inhibition in the treatment of spinal cord injury. World neurosurgery. 2014;82(3-4):e535-e9.

38. Fehlings MG, Theodore N, Harrop J, Maurais G, Kuntz C, Shaffrey CI, et al. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. Journal of neurotrauma. 2011;28(5):787-96.

39. Simonen M, Pedersen V, Weinmann O, Schnell L, Buss A, Ledermann B, et al. Systemic deletion of the myelin-associated outgrowth inhibitor Nogo-A improves regenerative and plastic responses after spinal cord injury. Neuron. 2003;38(2):201-11.

40. Farner L, Scheuren PS, Sharifi K, Emmenegger TM, Seif M, Hubli M, et al. Anti-Nogo-A NG101 treatment induces changes in spinal cord micro-and macrostructure following spinal cord injury. Nature Communications. 2026;17(1):4197.

41. Doncel-Pérez E, Guízar-Sahagún G, Grijalva-Otero I. From single to combinatorial therapies in spinal cord injuries for structural and functional restoration. Neural Regeneration Research. 2024;20(3):660.

42. Ahuja CS, Mothe A, Khazaei M, Badhiwala JH, Gilbert EA, Kooy D, et al. The leading edge: Emerging neuroprotective and neuroregenerative cell-based therapies for spinal cord injury. Stem cells translational medicine. 2020;9(12):1509-30.

43. Peyvandi H, Abbaszadeh H-A, Peyvandi AA, Niknazar S, Khoramgah MS, Darabi S, et al. Cell Therapy; A New and Safe Strategy for the Treatment of Spinal Cord Injury: A Review. Journal of Otorhinolaryngology and Facial Plastic Surgery. 2019;5(1):1-7.

44. Xia Y, Zhu J, Yang R, Wang H, Li Y, Fu C. Mesenchymal stem cells in the treatment of spinal cord injury: Mechanisms, current advances and future challenges. Frontiers in immunology. 2023;14:1141601.

45. Kulus M, Sibiak R, Stefańska K, Zdun M, Wieczorkiewicz M, Piotrowska-Kempisty H, et al. Mesenchymal stem/stromal cells derived from human and animal perinatal tissues—origins, characteristics, signaling pathways, and clinical trials. Cells. 2021;10(12):3278.

46. Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends in pharmacological sciences. 2020;41(9):653-64.

47. Munoz-Perez E, Gonzalez-Pujana A, Igartua M, Santos-Vizcaino E, Hernandez RM. Mesenchymal stromal cell secretome for the treatment of immune-mediated inflammatory diseases: latest trends in isolation, content optimization and delivery avenues. Pharmaceutics. 2021;13(11):1802.

48. Jiang D, Chen F-X, Zhou H, Lu Y-Y, Tan H, Yu S-J, et al. Bioenergetic crosstalk between mesenchymal stem cells and various ocular cells through the intercellular trafficking of mitochondria. Theranostics. 2020;10(16):7260.

49. Chen H, Chen X, Zhou Z-h, Zheng J-r, Lu Y, Lin P, et al. Mesenchymal stromal cell-mediated mitochondrial transfer unveils new frontiers in disease therapy. Stem Cell Research & Therapy. 2025;16(1):546.

50. Troiani Z, Chipman DE, Ryan TJ, Haider MN, Kowalski D, Hasanspahic B, et al. Efficacy of mesenchymal and embryonic stem cell therapy for the treatment of spinal cord injury: a systematic review and meta-analysis of human studies. Global spine journal. 2025;15(8):3969-81.

51. Bagno LL, Salerno AG, Balkan W, Hare JM. Mechanism of action of mesenchymal stem cells (MSCs): impact of delivery method. Expert opinion on biological therapy. 2022;22(4):449-63.

52. Vaquero J, Zurita M, Rico MA, Aguayo C, Bonilla C, Marin E, et al. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100/3 guideline. Cytotherapy. 2018;20(6):806-19.

53. Lee S, Nam H, Joo K-M, Lee S-H. Advances in neural stem cell therapy for spinal cord injury: safety, efficacy, and future perspectives. Neurospine. 2022;19(4):946.

54. Tiwari S, Khan S, Kumar SV, Rajak R, Sultana A, Pasha SA, et al. Efficacy and safety of neural stem cell therapy for spinal cord injury: a systematic literature review. Therapies. 2021;76(3):201-10.

55. Li Y, Gu Y, Wang Z, Wang Y, Jiang S, Wang K, et al. GelMA Hydrogel Encapsulating iPSC‐Derived Human Spinal Cord Organoids Enhances Neural Regeneration and Restores Motor Function in Rat Spinal Cord Injury. Journal of Biomedical Materials Research Part A. 2025;113(10):e38001.

56. Xu X, Liang Z, Lin Y, Rao J, Lin F, Yang Z, et al. Comparing the efficacy and safety of cell transplantation for spinal cord injury: A systematic review and Bayesian network meta-analysis. Frontiers in Cellular Neuroscience. 2022;16:860131.

57. Deng J, Zhang Y, Xie Y, Zhang L, Tang P. Cell transplantation for spinal cord injury: tumorigenicity of induced pluripotent stem cell‐derived neural stem/progenitor cells. Stem cells international. 2018;2018(1):5653787.

58. Hejrati N, Wong R, Khazaei M, Fehlings MG. How can clinical safety and efficacy concerns in stem cell therapy for spinal cord injury be overcome? Expert Opinion on Biological Therapy. 2023;23(9):883-99.

59. Kvistad CE, Kråkenes T, Gjerde C, Mustafa K, Rekand T, Bø L. Safety and clinical efficacy of mesenchymal stem cell treatment in traumatic spinal cord injury, multiple sclerosis and ischemic stroke–a systematic review and meta-analysis. Frontiers in neurology. 2022;13:891514.

60. Oliveira JT, Yanick C, Wein N, Gomez Limia CE. Neuron-Schwann cell interactions in peripheral nervous system homeostasis, disease, and preclinical treatment. Frontiers in cellular neuroscience. 2023;17:1248922.

61. Rao Z, Lin Z, Song P, Quan D, Bai Y. Biomaterial-based Schwann cell transplantation and Schwann cell-derived biomaterials for nerve regeneration. Frontiers in cellular neuroscience. 2022;16:926222.

62. Xuan X, Chu X, Wang R, Liu L, Li D, Bouloux PM, et al. Extracellular matrix protein anosmin-1 regulates Schwann cell-astrocyte interaction for regenerative axon targeting in dorsal root crush injury model. Cell transplantation. 2025;34:09636897251362107.

63. Anderson KD, Guest JD, Dietrich WD, Bartlett Bunge M, Curiel R, Dididze M, et al. Safety of autologous human Schwann cell transplantation in subacute thoracic spinal cord injury. Journal of neurotrauma. 2017;34(21):2950-63.

64. Yazdani SO, Hafizi M, Zali A-R, Atashi A, Ashrafi F, Seddighi A-S, et al. Safety and possible outcome assessment of autologous Schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury. Cytotherapy. 2013;15(7):782-91.

65. Monje PV. The properties of human Schwann cells: Lessons from in vitro culture and transplantation studies. Glia. 2020;68(4):797-810.

66. Barnett SC. Olfactory ensheathing cells: unique glial cell types? : SAGE Publications Sage CA: Los Angeles, CA; 2004.

67. Ursavas S, Darici H, Karaoz E. Olfactory ensheathing cells: Unique glial cells promising for treatments of spinal cord injury. Journal of neuroscience research. 2021;99(6):1579-97.

68. Phelps PE, Ha SM, Khankan RR, Mekonnen MA, Juarez G, Ingraham Dixie KL, et al. Olfactory ensheathing cells from adult female rats are hybrid glia that promote neural repair. Elife. 2025;13:RP95629.

69. Ingraham Dixie KL, Tierno AM, Thornton MA, Mekonnen MA, Dale EA, Zhong H, et al. Olfactory Ensheathing Cell Transplantation Combined With Electrical Epidural Stimulation as a Long‐Term Treatment for Severe Spinal Cord Injury in Female Fischer 344 Rats. European Journal of Neuroscience. 2026;64(4):e70648.

70. Yao R, Murtaza M, Velasquez JT, Todorovic M, Rayfield A, Ekberg J, et al. Olfactory ensheathing cells for spinal cord injury: sniffing out the issues. Cell transplantation. 2018;27(6):879-89.

71. Reshamwala R, Murtaza M, Chen M, Shah M, Ekberg J, Palipana D, et al. Designing a clinical trial with olfactory ensheathing cell transplantation-based therapy for spinal cord injury: a position paper. Biomedicines. 2022;10(12):3153.

72. Watzlawick R, Rind J, Sena ES, Brommer B, Zhang T, Kopp MA, et al. Olfactory ensheathing cell transplantation in experimental spinal cord injury: effect size and reporting bias of 62 experimental treatments: a systematic review and meta-analysis. PLoS biology. 2016;14(5):e1002468.

73. Huang H-y, Xiong M-j, Pu F-q, Liao J-x, Zhu F-q, Zhang W-j. Application and challenges of olfactory ensheathing cells in clinical trials of spinal cord injury. European Journal of Pharmacology. 2024;963:176238.

74. Haratizadeh S, Liu H, Li H, Adeli M, All AH. Biomaterials and cell-based therapy post spinal cord injury. Journal of Translational Medicine. 2025;23(1):1042.

75. Führmann T, Anandakumaran PN, Shoichet MS. Combinatorial therapies after spinal cord injury: how can biomaterials help? Advanced healthcare materials. 2017;6(10):1601130.

76. Han C, Jiao J, Gong C, Li J, Zhao M, Lu X. Multidimensional exploration of hydrogels as biological scaffolds for spinal cord regeneration: mechanisms and future perspectives. Frontiers in bioengineering and biotechnology. 2025;13:1576524.

77. Wang Y, Lv H-Q, Chao X, Xu W-X, Liu Y, Ling G-X, et al. Multimodal therapy strategies based on hydrogels for the repair of spinal cord injury. Military Medical Research. 2022;9(1):16.

78. Krylova SV, Feng D. The machinery of exosomes: biogenesis, release, and uptake. International journal of molecular sciences. 2023;24(2):1337.

79. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. science. 2020;367(6478):eaau6977.

80. Jan AT, Rahman S, Khan S, Tasduq SA, Choi I. Biology, pathophysiological role, and clinical implications of exosomes: a critical appraisal. Cells. 2019;8(2):99.

81. Wang J, Xing K, Zhang G, Li Z, Ding X, Leong DT. Surface components and biological interactions of extracellular vesicles. Acs Nano. 2025;19(9):8433-61.

82. Li C, Ni Y-Q, Xu H, Xiang Q-Y, Zhao Y, Zhan J-K, et al. Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal transduction and targeted therapy. 2021;6(1):383.

83. Ripoll L, Zickler AM, Vader P, El Andaloussi S, Verweij FJ, Van Niel G. Biology and therapeutic potential of extracellular vesicle targeting and uptake. Nature Reviews Molecular Cell Biology. 2026;27(5):358-76.

84. Zhang Y, Zhang C, Gao K, Li K, Fu M, Lv C. The Application Prospects and Challenges of Mesenchymal Stem Cell-Derived Exosomes in Spinal Cord Injury Repair. Current Stem Cell Research & Therapy. 2025.

85. Li X, Wang C, Du K, Wang J, Lin J, Yang C. Mesenchymal stem cell-derived exosomes: a promising therapeutic strategy for spinal cord injury. International Journal of Nanomedicine. 2025:15901-20.

86. Cai J, Wu J, Wang J, Li Y, Hu X, Luo S, et al. Extracellular vesicles derived from different sources of mesenchymal stem cells: therapeutic effects and translational potential. Cell & bioscience. 2020;10(1):69.

87. Waghdhare SS, Mahajan P, Kulkarni A. Umbilical Cord Mesenchymal Stem Cells Derived Exosomes, Characterization and Therapeutic Application in Translational Medicine.

88. Khoshsirat S, Keramatinia A, Khoramgah MS, Vafaei-Nezhad S, Niknazar S, Darabi S, et al. Exosome therapy in spinal cord injury: a review. Journal of Otorhinolaryngology and Facial Plastic Surgery. 2019;5(2):1-8.

89. Shi Y, Li Z, Pu Y, Wang Q, Cui Z, Qi L, et al. The potential mechanisms and regulatory roles of exosomal miRNA in neural repair after spinal cord injury. Frontiers in Cellular Neuroscience. 2025;19:1711454.

90. An J, Chen B, Zhang R, Tian D, Shi K, Zhang L, et al. Therapeutic potential of mesenchymal stem cell-derived exosomes in spinal cord injury. Molecular Neurobiology. 2025;62(1):1291-315.

91. Hwang J, Jang S, Kim C, Lee S, Jeong H-S. Role of stem cell-derived exosomes and microRNAs in spinal cord injury. International Journal of Molecular Sciences. 2023;24(18):13849.

92. Zhang A, Bai Z, Yi W, Hu Z, Hao J. Overexpression of miR-338-5p in exosomes derived from mesenchymal stromal cells provides neuroprotective effects by the Cnr1/Rap1/Akt pathway after spinal cord injury in rats. Neuroscience Letters. 2021;761:136124.

93. Nakazaki M, Lankford KL, Yokoyama T, Ukai R, Hirota R, Oka S, et al. The Pivotal Roles of Macrophages and Microglia in Mesenchymal Stromal/Stem Cell-Derived Small Extracellular Vesicle–Mediated Tissue Repair After Spinal Cord Injury. Frontiers in Bioscience-Landmark. 2026;31(4).

94. He X, Zhang J, Guo Y, Yang X, Huang Y, Hao D. Exosomal miR-9-5p derived from BMSCs alleviates apoptosis, inflammation and endoplasmic reticulum stress in spinal cord injury by regulating the HDAC5/FGF2 axis. Molecular immunology. 2022;145:97-108.

95. Kang J, Li Z, Zhi Z, Wang S, Xu G. MiR-21 derived from the exosomes of MSCs regulates the death and differentiation of neurons in patients with spinal cord injury. Gene Therapy. 2019;26(12):491-503.

96. Qin T, Li C, Xu Y, Qin Y, Jin Y, He R, et al. Local delivery of EGFR+ NSCs-derived exosomes promotes neural regeneration post spinal cord injury via miR-34a-5p/HDAC6 pathway. Bioactive materials. 2024;33:424-43.

97. Li D, Zhang P, Yao X, Li H, Shen H, Li X, et al. Exosomes derived from miR-133b-modified mesenchymal stem cells promote recovery after spinal cord injury. Frontiers in neuroscience. 2018;12:845.

98. Lai X, Wang Y, Wang X, Liu B, Rong L. miR-146a-5p-modified hUCMSC-derived exosomes facilitate spinal cord function recovery by targeting neurotoxic astrocytes. Stem cell research & therapy. 2022;13(1):487.

99. Liu W, Rong Y, Wang J, Zhou Z, Ge X, Ji C, et al. Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization. Journal of neuroinflammation. 2020;17(1):47.

100. Chopra M, Kumar H. Navigating the complexities of spinal cord injury: an overview of pathology, treatment strategies and clinical trials. Drug discovery today. 2025;30(6):104387.

101. Griffin JM, Bradke F. Therapeutic repair for spinal cord injury: combinatory approaches to address a multifaceted problem. EMBO molecular medicine. 2020;12(3):EMMM201911505.

102. Schepici G, Silvestro S, Mazzon E. Regenerative effects of exosomes-derived MSCs: an overview on spinal cord injury experimental studies. Biomedicines. 2023;11(1):201.

103. Xie B, Kang Y, Zhao S, Wu Z, Wu Z, Kuang X, et al. Hydrogel–exosome synergistic system: mechanisms, applications and future prospects in regenerative medicine. Biomaterials Science. 2026;14(12):3049-81.

104. Zhang L, Fan C, Hao W, Zhuang Y, Liu X, Zhao Y, et al. NSCs migration promoted and drug delivered exosomes‐collagen scaffold via a bio‐specific peptide for one‐step spinal cord injury repair. Advanced healthcare materials. 2021;10(8):2001896.

105. Fan M-H, Zhang X-Z, Jiang Y-L, Pi J-K, Zhang J-Y, Zhang Y-Q, et al. Exosomes from hypoxic urine-derived stem cells facilitate healing of diabetic wound by targeting SERPINE1 through miR-486-5p. Biomaterials. 2025;314:122893.

106. Le TH, Phan LMT. Nanotechnology‐Enhanced Stemcell Therapy for Precision Regeneration Medicine: Mechanistic Advances, Engineering Strategies, and Clinical Translation. Advanced Therapeutics. 2026;9(2):e00573.

107. Yuan T, Wang T, Zhang J, Liu P, Xu J, Gu Z, et al. Robust and multifunctional nanoparticles assembled from natural polyphenols and metformin for efficient spinal cord regeneration. Acs Nano. 2023;17(18):18562-75.

108. Shibata T, Tashiro S, Shibata S, Shinozaki M, Shindo T, Hashimoto S, et al. Rehabilitative training enhances therapeutic effect of human iPSC-derived neural stem/progenitor cells transplantation in chronic spinal cord injury. Stem Cells Translational Medicine. 2023;12(2):83-96.

109. Wu Y-Y, Gao Y-M, Feng T, Rao J-S, Zhao C. Enhancing functional recovery after spinal cord injury through neuroplasticity: a comprehensive review. International Journal of Molecular Sciences. 2025;26(14):6596.

110. Shen Y, Cao X, Lu M, Gu H, Li M, Posner DA. Current treatments after spinal cord injury: Cell engineering, tissue engineering, and combined therapies. Smart Medicine. 2022;1(1):e20220017.